3 OVERALL REVIEW CRITERIA AND IMPACT 3 FUNDING OPPORTUNITY ANNOUNCEMENT (FOA) SPECIFIC CRITERIA 7 ORGANIZATION AND STRUCTURE 8 CLINICAL TRIALS RESEARCH PROGRAM 9 CANCER CARE DELIVERY RESEARCH PROGRAM 10 OPERATIONS/DATA MANAGEMENT 12 ADDITIONAL REVIEW CRITERIA 14 PROTECTIONS FOR HUMAN SUBJECTS 14 INCLUSION OF WOMEN, MINORITIES, AND CHILDREN 14 RESOURCE SHARING PLAN 14 BUDGET AND PERIOD OF SUPPORT 14 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): Massey Cancer Center (MCC) will serve as the primary component site for an NCORP Minority/Underserved Community Site (MB-NCORP) UM-1 award in partnership with nine collaborating community component sites. The overall objectives of this partnership are to extend novel, innovative, and effective minority recruitment approaches to an expanded base of community component sites, increase opportunities for minority and medically underserved individuals to participate in Cancer Clinical Trial Research (CCTR), and to integrate Cancer Care Delivery Research (CCDR) into the overall MB-NCORP. Accordingly, the specific aims of this proposal are to (1) establish a research infrastructure that will further enable community component sites to conduct CCTR with an emphasis on trials relevant to minority and medically underserved populations, (2) conduct NCI-approved CCTR at the MCC primary component site and throughout the community component sites, and (3) integrate Cancer Care Delivery Research (CCDR) into the overall MB-NCORP. The research design of the MB-NCORP offers a full menu of cancer studies including those in cancer prevention and control, screening, treatment, imaging, and CCDR. The proposed research is relevant to the mission of the NCI as MCC and the community component sites will bring cancer clinical trials and research to low-income, minority, and medically underserved individuals who otherwise would not have access to such studies. These studies will address many diverse factors from patient, provider, organizational, and policy perspectives that contribute to known disparities in cancer detection, treatment, and outcomes. Targeting the minority/underserved populations in their communities is a critical step toward alleviating the cancer care disparities prevalent in these populations.
The proposed research is relevant to public health as it will bring cancer clinical trials and cancer care delivery research to minority and underserved individuals in their own communities. The inclusion of these individuals in the research will both broaden the applicability of the research and help to reduce the health cancer disparities in the minority and underserved populations of cancer patients.
|Tarhini, Ahmad A; Lee, Sandra J; Li, Xiaoxue et al. (2018) E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-?2b in Advanced Melanoma. Clin Cancer Res :|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121|
|Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812|
|Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340|
|Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2017) The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol 24:1853-1860|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14|